Publisher Copyright: © The Author(s) 2025.; Background: Efficacy of tumour necrosis factor inhibitors (TNFi) for peripheral arthritis in patients with psoriatic arthritis (PsA) has been established in randomized clinical trials that have used improvement in summated joint counts as an outcome. Whether joints at different anatomical locations might respond differentially to TNFi remains unknown. The aim of the s...
Funding Information: This work was supported by Novartis Pharma AG. EuroSpA was financially supported by Novartis. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit the manuscript. Publisher Copyright: © 2024 The Author(s).; Objectives: Real-world evidence is needed to inform treatment strategies for patients with PsA and axial SpA (axSpA) who h...